Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atr
January 22, 2025 17:00 ET | Source: Anthos Therapeutics Secondary endpoints also…
“India Global Forum’s mission more relevant than ever,” says Finance Minister Nirmala Sitharaman ahead of IGF Middle East and Africa 2024
India Global Forum's flagship event in UAE kicks off in Dubai on 25…
PACS INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into PACS Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP…
